From:	Taylor, Ethel (CDC/NCEZID/DFWED/EDEB)
To:	Christine.Thomas@tn.gov; Christian.Mackley@tn.gov; Dunn, John (CDC tn.gov); Mary-Margaret.Fill@tn.gov; Emma.Roth@tn.gov; Dilani.Goonewardene@tn.gov; Yackley, Jane (CDC tn.gov); rmcelroy1@health.nyc.gov; McPherson, Tristan (CDC health.nyc.gov); Slavinski, Sally (CDC health.nyc.gov); Ackelsberg, Joel (CDC health.nyc.gov); Ahuja, Shama (CDC health.nyc.gov); maiwilliams@kingcounty.gov; bdell@Kingcounty.gov; n-axie@kingcounty.gov; jloughran@kingcounty.gov; Brown, Catherine (CDC mass.gov); Clark, Julie D (DPH; eileen.mchale@mass.gov; Bolstorff, Barbara (CDC mass.gov); Herlihy, Rachel (CDC state.co.us); Comstock, Nicole (CDC state.co.us); Kerri Brown - CDPHE; Natalia Gayou - CDPHE; Jervis, Rachel (CDC state.co.us); Austin, Connie (CDC illinois.gov); Hillary.Spencer@Illinois.gov; bethany.hodge@ky.gov; Barger, Alexandra (CHFS DPH DEHP; Rush, Carrell (CDC ky.gov); douglas.thoroughman@ky.gov; Thomas, Deepam (CDC doh.nj.gov); claire.figi@nebraska.gov; Loeck, Brianna (CDC nebraska.gov); Stockdale, Kimberly; Schmitz, Ann (CDC flhealth.gov); Charles, Argentina (CDC flhealth.gov); Foster, Tricia (CDC flhealth.gov); Kathleen, Winter (CDC ky.gov); Lee, Nicole (CDC dhhs.nc.gov); DAngelo, Melanie; Morrison, Tammra; Evert,Nicole (DSHS); Vit.Kraushaar@cdph.ca.gov; Rodriguez,Gretchen (DSHS); Dang,Thi (DSHS); Wilson, Erica (CDC dhhs.nc.gov); carl.williams@dhhs.nc.gov; Hilary.Rosen@cdph.ca.gov
Cc:	Cope, Jennifer R. (CDC/NCEZID/DFWED/EDEB); Ranga, Srikar (CDC/NCEZID/DFWED/EDEB); Breazu, Robert (CDC/NCEZID/DFWED/EDEB); Waltenburg, Michelle (CDC/NCEZID/DHCPP/OD); Angelo, Kristina (CDC/NCEZID/DFWED/EDEB); Lamere, Elizabeth (CDC/NCEZID/DFWED/EDEB); Ngan, Kelly; Hunt, Travis; Kozler, Matthew; Lance, Susan (FDA/CFSAN); Gwathmey, Michael; Lance, Susan (CDC/NCEZID/DFWED/OD); McGarry, Sherri (CDC/NCEZID/DFWED/OD); McGarry, Sherri A (FDA/CFSAN); Dykes, Janet (CDC/NCEZID/DFWED/EDLB); Luquez, Carolina (CDC/NCEZID/DFWED/EDLB)
Subject:	Adverse Events from Botulism Investigation Close-out
Date:	Monday, June 24, 2024 3:25:00 PM

Dear Colleagues,

Please see below the close out summary regarding the recent investigation into adverse events from botulinum toxin injections. Thank you for your collaboration on this multistate effort, and please let me know if you have any questions.

Close Out Summary:

From March 2024 – June 2024 CDC, FDA, and state partners investigated reports of adverse events after receiving injections with counterfeit botulinum toxin products, products from unverified sources, or from individuals who were not following state or local requirements. A total of 17 people from 9 states were identified: California (2), Colorado (1), Florida (1), Illinois (2), Kentucky (1), New Jersey (1), New York (3), Tennessee (3), and Texas (3). Reaction onset dates ranged from 11/4/2023–4/11/2024. Reported ages ranged from 25 to 67 years (median 43 years); all were female. Thirteen of 17 (76%) people were hospitalized and 6 (35%) were treated with botulism antitoxin. Symptoms reported included blurry vision and double vision, drooping eyelids, difficulty swallowing, dry mouth, slurred speech, difficulty breathing, fatigue, and generalized weakness.

Additional information on counterfeit products can be found on FDA's website.

CDC issued the final investigation updates here and here and closed the investigation on 6/24/2024. Based on discussions with NORS, this event will not be reported to their system.

Thanks again,
Ethel

Ethel V. Taylor, DVM, MPH, DACVPM
CDR, US Public Health Service
Lead, National Surveillance Team
Enteric Diseases Epidemiology Branch

Division of Foodborne, Waterborne, and Environmental Diseases
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
Email: idp4@cdc.gov | Work: 404-488-4995